


Customer No. 28880

Confirmation No. 2382

IFW



PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number 10/734,917

Filing Date 12/12/2003

First Named Inventor David J. Dooley

Art Unit 1621

Examiner Name Not yet assigned

Total Number of Pages in This Submission

Attorney Docket Number PC25870A

**ENCLOSURES (Check all that apply)**

- |                                                                              |                                                                                                                                            |                                                                                         |
|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form                                | <input type="checkbox"/> Drawing(s)                                                                                                        | <input type="checkbox"/> After Allowance Communication to a Technology Center (TC)      |
| <input type="checkbox"/> Fee Attached                                        | <input type="checkbox"/> Licensing-related Papers                                                                                          | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences     |
| <input type="checkbox"/> Amendment/Reply                                     | <input type="checkbox"/> Petition                                                                                                          | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final                                         | <input type="checkbox"/> Petition to Convert to a Provisional Application                                                                  | <input type="checkbox"/> Proprietary Information                                        |
| <input type="checkbox"/> Affidavits/declaration(s)                           | <input type="checkbox"/> Power of Attorney, Revocation                                                                                     | <input type="checkbox"/> Status Letter                                                  |
| <input type="checkbox"/> Extension of Time Request                           | <input type="checkbox"/> Change of Correspondence Address                                                                                  | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):         |
| <input type="checkbox"/> Express Abandonment Request                         | <input type="checkbox"/> Terminal Disclaimer                                                                                               | Statement as Provided by 37 CFR 1.97(b)                                                 |
| <input checked="" type="checkbox"/> Information Disclosure Statement         | <input type="checkbox"/> Request for Refund                                                                                                | Return Post Card                                                                        |
| <input type="checkbox"/> Certified Copy of Priority Document(s)              | <input type="checkbox"/> CD, Number of CD(s) _____                                                                                         | Certificate of Mailing under 37 CFR 1.8                                                 |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application    | <b>Remarks</b>                                                                                                                             |                                                                                         |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | AUTHORIZATION TO CHARGE THE FEE AND ANY ADDITIONAL FEES AS NECESSARY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT 21-0718 IS HEREBY GIVEN. |                                                                                         |

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

|                    |                         |
|--------------------|-------------------------|
| Firm or Individual | Mehdi Ganjezadeh        |
| Signature          | <i>Mehdi Ganjezadeh</i> |
| Date               | June 8, 2004            |

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date \_\_\_\_\_

|                  |  |      |  |
|------------------|--|------|--|
| Typed or printed |  |      |  |
| Signature        |  | Date |  |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

P.O. Box 1450

Assistant Commissioner for Patents

Washington, D.C. 20231-1450

Alexandria, VA 22313-1450

on June 8, 2004  
Date

Inja Cho  
Signature

Inja Cho

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Docket No. PC25870A

IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

**Statement as Provided by 37 CFR 1.97(b)**

Dear Sir:

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Michael J. Fisher

Mehdi Ganjezadeh  
Registration No. 47,585  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-3831  
Fax (734) 622-2928

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

|       |   |    |   |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

**Complete if Known**

|                        |                 |
|------------------------|-----------------|
| Application Number     | 10/734,917      |
| Filing Date            | 12/12/2003      |
| First Named Inventor   | David J. Dooley |
| Art Unit               | 1621            |
| Examiner Name          | Unknown         |
| Attorney Docket Number | PC25870A        |

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | FOREIGN PATENT DOCUMENTS                                                          |                                   |                                                    |                                                                                 | T <sup>6</sup> |
|-----------------------|--------------------------|-----------------------------------------------------------------------------------|-----------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------|----------------|
|                       |                          | Foreign Patent Document                                                           | Publication<br>Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>Or Relevant Figures Appear |                |
|                       |                          | Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known) |                                   |                                                    |                                                                                 |                |
|                       | EP                       | 0641330 B1                                                                        | 10-17-2001                        | R. B. Silverman, et al.                            |                                                                                 |                |
|                       | WO                       | 98/17627 A1                                                                       | 04-30-1998                        | J. S. Bryans, et al.                               |                                                                                 |                |
|                       | WO                       | 99/21824 A1                                                                       | 05-06-1999                        | J. S. Bryans, et al.                               |                                                                                 |                |
|                       | WO                       | 00/76958 A2                                                                       | 12-21-2000                        | T. R. Belliotti, et al.                            |                                                                                 |                |
|                       | WO                       | 01/28978 A1                                                                       | 04-26-2001                        | J. S. Bryans, et al.                               |                                                                                 |                |
|                       | WO                       | 01/90052 A1                                                                       | 11-29-2001                        | J. S. Bryans, et al.                               |                                                                                 |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|                                                                                                                                               |   |                        |                   |                          |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|------------------------|-------------------|--------------------------|--|
| Substitute for form 1449B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |                        |                   | <b>Complete if Known</b> |  |
|                                                                                                                                               |   | Application Number     | 10/734,917        |                          |  |
|                                                                                                                                               |   | Filing Date            | December 12, 2003 |                          |  |
|                                                                                                                                               |   | First Named Inventor   | David J. Dooley   |                          |  |
|                                                                                                                                               |   | Group Art Unit         | 1621              |                          |  |
|                                                                                                                                               |   | Examiner Name          | Unknown           |                          |  |
|                                                                                                                                               |   | Attorney Docket Number | PC25870A          |                          |  |
| Sheet                                                                                                                                         | 2 | of                     | 2                 |                          |  |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |                                                                                                                                                                                                                                                                 |                |
|----------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials <sup>2</sup>                     | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                                    |                       | M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; Vol.9, No. 10                                      |                |
|                                                    |                       | A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290                                                                                                                                              |                |
|                                                    |                       | R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199                                                                                                                                                         |                |
|                                                    |                       | D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome" Current opinions in Rheumatology 2001;13:117-127                                                                                                                              |                |
|                                                    |                       | B. L. EHRENBERG, et al., "Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep", 1997, pp A278-A279, Vol. 48                                                                                                                             |                |
|                                                    |                       | E. K. GUYMER, et al., "An approach to managing fibromyalgia" Medicine Today 2002:58-59; Vol. 3, No. 12                                                                                                                                                          |                |
|                                                    |                       | L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8                                                                                                                                                                                     |                |
|                                                    |                       | L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and eeg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2                                                                                              |                |
|                                                    |                       | I. SELAK, "Pregabalin (Pfizer)" Current opinion in investigational drugs, current drugs, Lond, GB 2001:828-834; Vol. 2, No. 6                                                                                                                                   |                |
|                                                    |                       | F. WOLFE, et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee" Arthritis Rheum 1990; 33:160-72                                                                     |                |
|                                                    |                       | M. B. YUNUS, "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217                                                                                                                                        |                |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313